Belviq Lawsuits For Pancreatic Cancer, Colon Cancer, Rectal Cancer, Lung Cancer
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
In February 2020 there was a Belviq recall due to cancer cases observed in a Belviq safety clinical trial. The Belviq FDA Drug Safety Communication announcing this Belviq recall, “FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market”, noted that excess cases of pancreatic cancer, colon cancer, rectal cancer, and lung cancer were observed. This Belviq recall has resulted in Belviq lawsuits being filed against the responsible pharmaceutical company, Eisai Inc.
The Data Summary section of the Belviq FDA Drug Safety Communication set forth these findings from the Belviq safety clinical trial:
Imbalances in specific cancers including pancreatic, colorectal, and lung contributed to the observed overall imbalance in cancer cases. There was no apparent difference in the incidence of cancer over the initial months of treatment, but the imbalance increased with longer duration on [Belviq (lorcaserin)].
According to the FDA, these are some of the specific types of cancer associated with Belviq:
- Pancreatic Cancer
- Colorectal Cancer
- Colon Cancer
- Rectal Cancer
- Lung Cancer
Our law firm is investigating possible Belviq lawsuits where patients have been diagnosed with cancer, including but not limited to the types listed above.
We encourage you to submit a Belviq Lawsuits Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
Most Recent Article About Belviq
Following the Belviq recall in February 2020 some of those patients on Belviq developing cancer filed Belviq lawsuits alleging a failure to warn about the risk of cancer associated with Belviq.
We are investigating possible Belviq lawsuits that involve patients on Belviq developing cancer. At the present time, our focus for these Belviq lawsuits is pancreatic cancer, colon cancer, rectal cancer, and lung cancer cases. Let us know if we can help you or a family member by submitting an online Belviq Case Evaluation form, sending me an email, or calling us (800-426-9535).
To read more of this article, click below:
The Belviq recall was announced after the FDA concluded that the potential risk of cancer associated with Belviq (lorcaserin) outweighs its benefits. The FDA noted there was a numerical imbalance in the number of patients on Belviq developing cancer, then pointed out pancreatic cancer, colorectal cancer, and lung cancer, in particular.
For more information relevant to the Belviq lawsuits being filed against the drug company Eisai for failure to warn following the Belviq recall, we direct you to this February 13, 2020, FDA Drug Safety Communication: “FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market“.[Read article in full at original source]
Earlier articles about Belviq by attorney Tom Lamb on the Side Effects Blog:
- Belviq Recall Due To Certain Cancers: Pancreatic, Colon, Rectal, And Lung
- Weight-Loss Medicine Belviq Increased Risk Of Cancers Says FDA Drug Safety Communication